Veru 4/1/2024 Earnings Report

Veru EPS Results

• Actual EPS: -$0.90
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Veru Revenue Results

• Actual Revenue: $2.14 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Veru Announcement Details

• Date: 4/1/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Veru (NASDAQ:VERU) is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19. In parallel, Veru is developing toremifene, a selective estrogen receptor modulator repurposed to address chemotherapy-induced side effects and support women’s health applications. The company’s pipeline also encompasses exploratory programs aimed at targeting key drivers of cancer progression and acute inflammatory responses.

Founded in 2010 (formerly operating as Veru Healthcare) by Dr. Mark A. Enyedy, who serves as President and Chief Executive Officer, Veru has conducted clinical studies across North America, Europe and Asia. The company maintains collaborations with academic institutions and contract research organizations to execute multi-center trials, and it has secured manufacturing partnerships to support planned commercial supply. Veru’s leadership team combines expertise in pharmaceutical development, regulatory affairs and oncology drug commercialization to guide late-stage program advancement.